Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (≥50 Years).

NCT03450915 is registered in ClinicalTrials.gov with BiondVax Pharmaceuticals ltd. as lead sponsor.

NCT NCT03450915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03450915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (≥50 Years).
Lead sponsor
BiondVax Pharmaceuticals ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2018
Completion date
October 23, 2020
Enrollment
12,460 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza